PT3111954T - Métodos de tratamento da espondilite anquilosante usando anticorpos anti-il-17 - Google Patents

Métodos de tratamento da espondilite anquilosante usando anticorpos anti-il-17

Info

Publication number: PT3111954T
Authority: PT; Portugal
Prior art keywords: antibodies; methods; ankylosing spondylitis; treating ankylosing; treating
Prior art date: 2010-11-05

Application number

PT16163440T

Other languages

English (en)

Inventor

Mpofu Shepard

Richards Hanno

Thangavelu Karthinathan

Machacek Matthias

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-05

Filing date

2011-11-04

Publication date

2019-07-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44906168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3111954(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-11-04 Application filed by Novartis Ag filed Critical Novartis Ag

2019-07-10 Publication of PT3111954T publication Critical patent/PT3111954T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicinal Preparation (AREA)

PT16163440T 2010-11-05 2011-11-04 Métodos de tratamento da espondilite anquilosante usando anticorpos anti-il-17 PT3111954T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41053310P	2010-11-05	2010-11-05

Publications (1)

Publication Number	Publication Date
PT3111954T true PT3111954T (pt)	2019-07-10

Family

ID=44906168

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT201870011T PT3757126T (pt)	2010-11-05	2011-11-04	Métodos de tratamento da artrite psoriática utilizando antagonistas da il-17
PT16163440T PT3111954T (pt)	2010-11-05	2011-11-04	Métodos de tratamento da espondilite anquilosante usando anticorpos anti-il-17

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT201870011T PT3757126T (pt)	2010-11-05	2011-11-04	Métodos de tratamento da artrite psoriática utilizando antagonistas da il-17

Country Status (31)

Country	Link
US (10)	US9744234B2 (pt)
EP (6)	EP3542820A1 (pt)
JP (8)	JP2014503482A (pt)
KR (5)	KR20180019247A (pt)
CN (2)	CN104800844A (pt)
AU (1)	AU2011325134B2 (pt)
BR (1)	BR112013011176A2 (pt)
CA (2)	CA2813849C (pt)
CL (1)	CL2013001213A1 (pt)
CY (1)	CY1121802T1 (pt)
DE (1)	DE20187001T1 (pt)
DK (2)	DK3111954T3 (pt)
ES (3)	ES2733712T3 (pt)
FI (1)	FI3757126T3 (pt)
HR (2)	HRP20251174T1 (pt)
HU (1)	HUE044038T2 (pt)
IL (4)	IL311014A (pt)
LT (2)	LT3111954T (pt)
MA (1)	MA34647B1 (pt)
MX (1)	MX362591B (pt)
PH (1)	PH12013500890A1 (pt)
PL (1)	PL3111954T3 (pt)
PT (2)	PT3757126T (pt)
RS (1)	RS67377B1 (pt)
RU (1)	RU2582937C2 (pt)
SG (2)	SG10201505624VA (pt)
SI (2)	SI3111954T1 (pt)
SM (1)	SMT202500423T1 (pt)
TR (1)	TR201909531T4 (pt)
TW (3)	TWI604851B (pt)
WO (1)	WO2012059598A2 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20130080790A (ko)	2010-05-20	2013-07-15	아블린쓰 엔.브이.	Ｈｅｒ３와 관련된 생물학적 물질들
MX362591B (es)	2010-11-05	2019-01-25	Novartis Ag	Uso de antagonistas de il-17.
UA117218C2 (uk)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
HRP20201513T1 (hr)	2011-10-11	2020-12-11	Viela Bio, Inc.	Cd40l-specifični tn3-izvedeni skeleti i postupci njihove uporabe
WO2013116682A1 (en)	2012-02-02	2013-08-08	Ensemble Therapeutics Corporation	Macrocyclic compounds for modulating il-17
US20140004131A1 (en)	2012-05-04	2014-01-02	Novartis Ag	Antibody formulation
WO2014155278A2 (en)	2013-03-26	2014-10-02	Novartis Ag	Methods of treating autoimmune diseases using il-17 antagonists
US9688769B2 (en)	2013-10-22	2017-06-27	Novimmune S.A.	Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkers
JP2017508446A (ja) *	2014-01-28	2017-03-30	北京韓美薬品有限公司	二機能性融合タンパク質及びその製造方法並びに使用
CN106456756B (zh)	2014-05-13	2021-04-23	免疫医疗有限公司	用于治疗非小细胞肺癌的抗-b7-h1和抗-ctla-4抗体
US11548940B2 (en)	2014-05-15	2023-01-10	Rani Therapeutics, Llc	Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CA3198322A1 (en)	2014-05-15	2015-11-19	Rani Therapeutics, Llc	Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
FR3021976B1 (fr) *	2014-06-06	2018-11-02	Hospices Civils De Lyon	Marqueur biologique permettant d'evaluer le niveau pro-inflammatoire dependant de la contribution fonctionnelle de l'il-17 chez un individu
US20160002326A1 (en) *	2014-06-10	2016-01-07	Abbvie Inc.	Compositions and methods for treating rheumatoid arthritis
NL2013007B1 (en) *	2014-06-16	2016-07-05	Ablynx Nv	Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
MX2017003216A (es) *	2014-09-10	2017-05-23	Novartis Ag	Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
ES2941234T3 (es) *	2014-10-22	2023-05-19	Armo Biosciences Inc	Métodos de uso de la interleucina-10 para el tratamiento de enfermedades y trastornos
AR103172A1 (es) *	2014-12-22	2017-04-19	Novartis Ag	Reducción selectiva de residuos de cisteina en anticuerpos il-17
AR103173A1 (es) *	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3265107B1 (en)	2015-03-02	2024-10-02	180 Therapeutics LP	Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist
EP3167892A1 (en)	2015-11-10	2017-05-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for preventing or treating imflammatory bowel diseases
IL297775A (en) *	2015-10-19	2022-12-01	Novartis Ag	Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
US20190183991A1 (en) *	2016-08-23	2019-06-20	Csl Behring Gmbh	Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
US20210179702A1 (en) *	2017-11-02	2021-06-17	Novartis Ag	Method of treating tendinopathy using interleukin-17 (il-17)
GB201719447D0 (en) *	2017-11-23	2018-01-10	Ucb Biopharma Sprl	Pharmaceutical composition
EP3790576A1 (en) *	2018-05-09	2021-03-17	Novartis Ag	Use of canakinumab
US20210340200A1 (en) *	2018-09-26	2021-11-04	Viela Bio, Inc.	Cd40l antagonist and uses thereof
CA3125236A1 (en) *	2019-01-22	2020-07-30	F. Hoffmann-La Roche Ag	Methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosis using an inhibitor of bruton's tyrosine kinase
US11634485B2 (en)	2019-02-18	2023-04-25	Eli Lilly And Company	Therapeutic antibody formulation
KR102169901B1 (ko) *	2019-05-17	2020-10-26	연세대학교 산학협력단	Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
CN110179746A (zh)	2019-05-17	2019-08-30	通化东宝生物科技有限公司	一种稳定的苏金单抗注射剂及其制备方法
EP4010077A1 (en) *	2019-08-05	2022-06-15	Evelo Biosciences, Inc.	Compositions and methods of treating psoriasis and atopic dermatitis using prevotella histicola
TW202539734A (zh) *	2019-09-20	2025-10-16	瑞士商諾華公司	使用白細胞介素-17（il-17）拮抗劑治療自體免疫性疾病之方法
JP2023502103A (ja)	2019-11-19	2023-01-20	ノバルティスアーゲー	インターロイキン－１７（ｉｌ－１７）アンタゴニストを用いてループス腎炎を治療する方法
CN112915201B (zh) *	2019-12-06	2023-06-27	珠海市丽珠单抗生物技术有限公司	包含抗il-17抗体的液体制剂
WO2021146850A1 (en) *	2020-01-20	2021-07-29	Tsinghua University	A critical role of febrile temperature in regulating interleukin (il) -17 producing cells via smad4
WO2022113105A1 (en) *	2020-11-25	2022-06-02	Dr. Reddy's Laboratories Limited	Stable therapeutic protein formulation and methods of making the same
TW202241505A (zh) *	2021-01-04	2022-11-01	大陸商江蘇恆瑞醫藥股份有限公司	抗il-17抗體治療自體免疫性疾病和炎症的方法
TW202246329A (zh) *	2021-03-03	2022-12-01	大陸商蘇州盛迪亞生物醫藥有限公司	抗il-17抗體治療自體免疫性疾病和炎症的方法
KR102339377B1 (ko) *	2021-03-29	2021-12-13	김지혜	사용자 맞춤형 문화 예술 컨텐츠 제공 방법 및 장치
KR20240024929A (ko) *	2021-06-21	2024-02-26	브리스톨-마이어스 스큅 컴퍼니	고농도 동결건조 생물제제 약물 제품의 재구성 시간을 감소시키기 위한 수크로스, 만니톨 및 글리신의 용도
CN114306594A (zh) *	2021-12-21	2022-04-12	华中科技大学同济医学院附属协和医院	地舒单抗在制备治疗膝关节骨性关节炎的药物中的应用
EP4406553A1 (en)	2023-01-27	2024-07-31	Fresenius Kabi Deutschland GmbH	Stable secukinumab biopharmaceutical composition
WO2024156841A1 (en)	2023-01-27	2024-08-02	Fresenius Kabi Deutschland Gmbh	Biopharmaceutical composition
WO2025071335A1 (ko) *	2023-09-27	2025-04-03	삼성바이오에피스 주식회사	항-il-17 항체의 안정한 액상 제형

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0565233A (ja)	1991-03-08	1993-03-19	Mitsui Toatsu Chem Inc	モノクローナル抗体含有凍結乾燥製剤
US5250442A (en) *	1993-04-08	1993-10-05	Orestes Cabezas	Method of treating rheumatoid arthritis using tetracycline
US6309636B1 (en) *	1995-09-14	2001-10-30	Cancer Research Institute Of Contra Costa	Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
EP0852951A1 (de)	1996-11-19	1998-07-15	Roche Diagnostics GmbH	Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20050147609A1 (en)	1998-05-15	2005-07-07	Genentech, Inc.	Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
JP2000186046A (ja)	1998-10-14	2000-07-04	Snow Brand Milk Prod Co Ltd	慢性関節リウマチ治療剤及び診断方法
PT1133558E (pt)	1998-11-27	2007-01-31	Ucb Sa	Composições e métodos para aumentar a mineralização óssea
US20040009535A1 (en)	1998-11-27	2004-01-15	Celltech R&D, Inc.	Compositions and methods for increasing bone mineralization
JP4159682B2 (ja)	1998-12-22	2008-10-01	株式会社クラレ	止血材
DE60235013D1 (de)	2001-07-25	2010-02-25	Facet Biotech Corp	Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
MXPA04004459A (es)	2001-11-09	2005-05-16	Johnson & Johnson	Composiciones liofilizadas de anticuerpo monoclonal.
JP4662714B2 (ja)	2002-03-01	2011-03-30	セルテックアールアンドディーインコーポレイテッド	骨密度を増減させる方法
AU2003276430A1 (en)	2002-06-14	2003-12-31	Stowers Institute For Medical Research	Wise/sost nucleic acid sequences and amino acid sequences
US6974701B2 (en)	2003-03-21	2005-12-13	Hemovations, Llc	Erythrocyte sedimentation rate (ESR) test measurement instrument of unitary design and method of using the same
NZ544618A (en)	2003-06-16	2009-02-28	Celltech R & D Inc	Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en)	2003-09-22	2013-06-11	University Of Connecticut	Sclerostin and the inhibition of WNT signaling and bone formation
US8039642B2 (en)	2003-12-09	2011-10-18	Life Technologies Corporation	Pyrenyloxysulfonic acid fluorescent agents
GB0417487D0 (en)	2004-08-05	2004-09-08	Novartis Ag	Organic compound
JP3936365B2 (ja)	2004-09-14	2007-06-27	ソニーケミカル＆インフォメーションデバイス株式会社	機能素子実装モジュール及びその製造方法
NZ561137A (en) *	2005-03-08	2011-09-30	Pharmacia & Upjohn Co Llc	Stable anti-CTLA-4 antibody compositions with chelating agents
US7592429B2 (en)	2005-05-03	2009-09-22	Ucb Sa	Sclerostin-binding antibody
US8003108B2 (en)	2005-05-03	2011-08-23	Amgen Inc.	Sclerostin epitopes
WO2007056188A1 (en)	2005-11-04	2007-05-18	President And Fellows Of Harvard College	Synthesis of inhibitors of ftsz
MY149159A (en)	2005-11-15	2013-07-31	Hoffmann La Roche	Method for treating joint damage
EP1977763A4 (en)	2005-12-28	2010-06-02	Chugai Pharmaceutical Co Ltd	ANTIBODY-CONTAINING STABILIZING PREPARATION
US8012477B2 (en) *	2006-01-31	2011-09-06	Novartis Ag	Methods of treating multiple myeloma using IL-17 binding molecules
TW200815469A (en)	2006-06-23	2008-04-01	Astrazeneca Ab	Compounds
MX2009002418A (es)	2006-09-05	2009-04-23	Medarex Inc	Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
WO2008029908A1 (fr)	2006-09-07	2008-03-13	Kyowa Hakko Kirin Co., Ltd.	Préparation pharmaceutique lyophilisée stable comprenant un anticorps
UA99716C2 (ru) *	2006-10-02	2012-09-25	Кирин-Амген Инк.	Антитело, которое специфично связывает человеческий il-17 рецептор а (il-17ra)
US7767206B2 (en)	2006-10-02	2010-08-03	Amgen Inc.	Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US20100036091A1 (en)	2006-11-10	2010-02-11	Amgen Inc.	Antibody-based diagnostics and therapeutics
US20100015665A1 (en)	2006-11-10	2010-01-21	Ucb Pharma S.A.	Antibodies and diagnostics
MX2009008096A (es)	2007-02-02	2009-08-07	Novartis Ag	Moduladores de los componentes de enlace de esclerostatina para el tratamiento de trastornos relacionados con los huesos.
JP2010524846A (ja)	2007-03-20	2010-07-22	イーライリリーアンドカンパニー	抗スクレロスチン抗体
EA200970880A1 (ru)	2007-03-22	2010-02-26	Имклоун Элэлси	Стабильные композиции на основе антител
US20100209434A1 (en)	2007-03-30	2010-08-19	Medimmune, Llc	Antibody formulation
EP2171449A2 (en)	2007-06-20	2010-04-07	Schering Corporation	Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
US7720605B2 (en)	2007-06-22	2010-05-18	Weyerhaeuser Nr Company	Identifying vegetation attributes from LiDAR data
CL2008002775A1 (es)	2007-09-17	2008-11-07	Amgen Inc	Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI489993B (zh)	2007-10-12	2015-07-01	Novartis Ag	骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
CN101896201A (zh)	2007-12-14	2010-11-24	安进公司	使用抗硬骨素抗体治疗骨折的方法
EP3002299A1 (en)	2008-06-03	2016-04-06	AbbVie Inc.	Dual variable domain immunoglobulins and uses thereof
US20090301682A1 (en)	2008-06-05	2009-12-10	Baker Hughes Incorporated	Casting furnace method and apparatus
TW201012475A (en)	2008-07-08	2010-04-01	Abbott Lab	Prostaglandin E2 dual variable domain immunoglobulins and uses thereof
NZ591484A (en)	2008-09-29	2012-09-28	Roche Glycart Ag	Antibodies against human il 17 and uses thereof
US20110293605A1 (en)	2008-11-12	2011-12-01	Hasige Sathish	Antibody formulation
FR2938547B1 (fr)	2008-11-14	2012-11-16	Total Raffinage Marketing	Liant synthetique clair
WO2010065491A2 (en)	2008-12-01	2010-06-10	Carolus Therapeutics, Inc.	Methods of treating inflammatory disorders
RU2011140335A (ru)	2009-03-05	2013-04-10	Эбботт Лэборетриз	Связывающие il-17 белки
HRP20180301T1 (hr)	2010-10-08	2018-03-23	Novartis Ag	Postupci liječenja psorijaze uporabom il-17 antagonista
MX362591B (es)	2010-11-05	2019-01-25	Novartis Ag	Uso de antagonistas de il-17.
TW201307845A (zh) *	2010-12-13	2013-02-16	Novartis Ag	預測方法及利用ｉｌ－１７拮抗劑治療關節炎的方法
KR20140097178A (ko)	2011-11-21	2014-08-06	노파르티스 아게	IL-17 길항제 및 건선성 관절염 (PsA) 반응 또는 비-반응 대립유전자를 이용하여 PsA를 치료하는 방법
CA2870025A1 (en)	2012-04-20	2013-10-24	Novartis Ag	Methods of treating ankylosing spondylitis using il-17 antagonists
WO2014155278A2 (en)	2013-03-26	2014-10-02	Novartis Ag	Methods of treating autoimmune diseases using il-17 antagonists
IL297775A (en)	2015-10-19	2022-12-01	Novartis Ag	Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
US11280479B2 (en)	2017-10-18	2022-03-22	The Sloan Company	Sign box light module

2011
- 2011-11-04 MX MX2013005060A patent/MX362591B/es active IP Right Grant
- 2011-11-04 KR KR1020187004058A patent/KR20180019247A/ko not_active Ceased
- 2011-11-04 RS RS20251090A patent/RS67377B1/sr unknown
- 2011-11-04 EP EP19162707.4A patent/EP3542820A1/en not_active Withdrawn
- 2011-11-04 CA CA2813849A patent/CA2813849C/en active Active
- 2011-11-04 DE DE20187001.1T patent/DE20187001T1/de active Pending
- 2011-11-04 WO PCT/EP2011/069476 patent/WO2012059598A2/en not_active Ceased
- 2011-11-04 KR KR1020167014431A patent/KR20160067984A/ko not_active Ceased
- 2011-11-04 US US13/877,585 patent/US9744234B2/en active Active
- 2011-11-04 LT LTEP16163440.7T patent/LT3111954T/lt unknown
- 2011-11-04 JP JP2013537154A patent/JP2014503482A/ja active Pending
- 2011-11-04 SG SG10201505624VA patent/SG10201505624VA/en unknown
- 2011-11-04 SM SM20250423T patent/SMT202500423T1/it unknown
- 2011-11-04 SG SG2013023064A patent/SG189138A1/en unknown
- 2011-11-04 KR KR1020187034385A patent/KR20180129991A/ko not_active Ceased
- 2011-11-04 HR HRP20251174TT patent/HRP20251174T1/hr unknown
- 2011-11-04 TR TR2019/09531T patent/TR201909531T4/tr unknown
- 2011-11-04 CN CN201510199026.8A patent/CN104800844A/zh active Pending
- 2011-11-04 DK DK16163440.7T patent/DK3111954T3/da active
- 2011-11-04 EP EP11778903.2A patent/EP2635303A2/en not_active Withdrawn
- 2011-11-04 PL PL16163440T patent/PL3111954T3/pl unknown
- 2011-11-04 EP EP20187001.1A patent/EP3757126B1/en active Active
- 2011-11-04 SI SI201131750T patent/SI3111954T1/sl unknown
- 2011-11-04 EP EP21180656.7A patent/EP3912640B1/en active Active
- 2011-11-04 BR BR112013011176-3A patent/BR112013011176A2/pt not_active IP Right Cessation
- 2011-11-04 TW TW100140410A patent/TWI604851B/zh active
- 2011-11-04 TW TW105142587A patent/TWI618543B/zh active
- 2011-11-04 RU RU2013125775/15A patent/RU2582937C2/ru active
- 2011-11-04 ES ES16163440T patent/ES2733712T3/es active Active
- 2011-11-04 IL IL311014A patent/IL311014A/en unknown
- 2011-11-04 ES ES20187001T patent/ES2804624T3/es active Active
- 2011-11-04 TW TW104103341A patent/TWI616204B/zh active
- 2011-11-04 KR KR1020157003096A patent/KR20150020734A/ko not_active Ceased
- 2011-11-04 EP EP16163440.7A patent/EP3111954B1/en not_active Revoked
- 2011-11-04 CA CA3116725A patent/CA3116725C/en active Active
- 2011-11-04 AU AU2011325134A patent/AU2011325134B2/en not_active Expired - Fee Related
- 2011-11-04 PT PT201870011T patent/PT3757126T/pt unknown
- 2011-11-04 FI FIEP20187001.1T patent/FI3757126T3/fi active
- 2011-11-04 ES ES21180656T patent/ES3030036T3/es active Active
- 2011-11-04 KR KR1020137011539A patent/KR20140008305A/ko not_active Ceased
- 2011-11-04 LT LTEP20187001.1T patent/LT3757126T/lt unknown
- 2011-11-04 HU HUE16163440A patent/HUE044038T2/hu unknown
- 2011-11-04 PH PH1/2013/500890A patent/PH12013500890A1/en unknown
- 2011-11-04 CN CN2011800529537A patent/CN103189074A/zh active Pending
- 2011-11-04 SI SI201132138T patent/SI3757126T1/sl unknown
- 2011-11-04 DK DK20187001.1T patent/DK3757126T3/da active
- 2011-11-04 EP EP22180976.7A patent/EP4116325A1/en active Pending
- 2011-11-04 PT PT16163440T patent/PT3111954T/pt unknown
2013
- 2013-03-18 IL IL225309A patent/IL225309B/en active IP Right Grant
- 2013-05-03 MA MA35873A patent/MA34647B1/fr unknown
- 2013-05-03 CL CL2013001213A patent/CL2013001213A1/es unknown
2015
- 2015-11-30 JP JP2015232562A patent/JP6049843B2/ja active Active
2016
- 2016-07-14 JP JP2016139469A patent/JP6250109B2/ja active Active
2017
- 2017-07-20 US US15/654,854 patent/US10363307B2/en active Active
- 2017-11-21 JP JP2017223669A patent/JP6515168B2/ja active Active
2018
- 2018-10-24 IL IL262559A patent/IL262559B/en unknown
2019
- 2019-04-12 JP JP2019076324A patent/JP2019142912A/ja active Pending
- 2019-06-12 US US16/439,423 patent/US20190307880A1/en not_active Abandoned
- 2019-06-26 HR HRP20191162TT patent/HRP20191162T1/hr unknown
- 2019-07-03 CY CY20191100708T patent/CY1121802T1/el unknown
2020
- 2020-03-19 US US16/824,613 patent/US11534491B2/en active Active
- 2020-12-18 US US17/127,758 patent/US20210128726A1/en not_active Abandoned
2021
- 2021-02-02 US US17/165,729 patent/US20210177966A1/en not_active Abandoned
- 2021-03-01 JP JP2021031383A patent/JP2021104995A/ja active Pending
- 2021-04-25 IL IL282625A patent/IL282625A/en unknown
- 2021-12-08 US US17/545,894 patent/US12465635B2/en active Active
2022
- 2022-10-21 US US18/048,797 patent/US20230293683A1/en active Pending
- 2022-12-02 US US18/061,221 patent/US20230346926A1/en active Pending
2023
- 2023-05-23 JP JP2023084472A patent/JP2023109910A/ja active Pending
2025
- 2025-02-24 US US19/061,831 patent/US20250205332A1/en active Pending
- 2025-03-04 JP JP2025034128A patent/JP2025102772A/ja active Pending

Also Published As

Publication number	Publication date
JP6515168B2 (ja)	2019-05-15
US20200276305A1 (en)	2020-09-03
CA2813849A1 (en)	2012-05-10
JP2016065094A (ja)	2016-04-28
RU2013125775A (ru)	2014-12-10
CY1121802T1 (el)	2020-07-31
TR201909531T4 (tr)	2019-07-22
PT3757126T (pt)	2025-11-13
JP2018065826A (ja)	2018-04-26
US20130209480A1 (en)	2013-08-15
MA34647B1 (fr)	2013-11-02
TWI618543B (zh)	2018-03-21
TWI616204B (zh)	2018-03-01
CA2813849C (en)	2021-06-15
HRP20191162T1 (hr)	2019-10-04
JP2017002064A (ja)	2017-01-05
US20230346926A1 (en)	2023-11-02
US20250205332A1 (en)	2025-06-26
ES2733712T3 (es)	2019-12-02
AU2011325134B2 (en)	2014-10-23
EP3757126B1 (en)	2025-09-03
IL311014A (en)	2024-04-01
US11534491B2 (en)	2022-12-27
US20230293683A1 (en)	2023-09-21
CA3116725C (en)	2023-10-24
TW201517917A (zh)	2015-05-16
JP6049843B2 (ja)	2016-12-21
JP2025102772A (ja)	2025-07-08
HUE044038T2 (hu)	2019-09-30
WO2012059598A3 (en)	2012-09-27
ES2804624T3 (en)	2026-01-23
MX2013005060A (es)	2013-06-28
US12465635B2 (en)	2025-11-11
US20180008706A1 (en)	2018-01-11
DE20187001T1 (de)	2021-04-01
KR20160067984A (ko)	2016-06-14
SG189138A1 (en)	2013-05-31
RU2582937C2 (ru)	2016-04-27
CN103189074A (zh)	2013-07-03
EP3542820A1 (en)	2019-09-25
EP3912640A1 (en)	2021-11-24
EP3912640B1 (en)	2025-03-05
WO2012059598A2 (en)	2012-05-10
US20190307880A1 (en)	2019-10-10
AU2011325134A1 (en)	2013-04-04
KR20140008305A (ko)	2014-01-21
EP3111954B1 (en)	2019-04-03
CN104800844A (zh)	2015-07-29
EP3111954A1 (en)	2017-01-04
JP2014503482A (ja)	2014-02-13
IL262559B (en)	2022-06-01
PL3111954T3 (pl)	2019-10-31
SMT202500423T1 (it)	2026-01-12
IL225309B (en)	2021-05-31
EP2635303A2 (en)	2013-09-11
LT3111954T (lt)	2019-07-10
KR20180129991A (ko)	2018-12-05
EP3757126A1 (en)	2020-12-30
SG10201505624VA (en)	2015-09-29
JP2023109910A (ja)	2023-08-08
DK3111954T3 (da)	2019-07-15
LT3757126T (lt)	2025-12-10
US20220193234A1 (en)	2022-06-23
JP2019142912A (ja)	2019-08-29
US9744234B2 (en)	2017-08-29
EP4116325A1 (en)	2023-01-11
RS67377B1 (sr)	2025-11-28
KR20150020734A (ko)	2015-02-26
KR20180019247A (ko)	2018-02-23
IL262559A (en)	2018-12-31
SI3111954T1 (sl)	2019-08-30
BR112013011176A2 (pt)	2020-09-01
US10363307B2 (en)	2019-07-30
IL225309A0 (en)	2013-06-27
ES3030036T3 (en)	2025-06-26
SI3757126T1 (sl)	2025-12-31
TW201726170A (zh)	2017-08-01
TWI604851B (zh)	2017-11-11
JP6250109B2 (ja)	2017-12-20
MX362591B (es)	2019-01-25
US20210128726A1 (en)	2021-05-06
CL2013001213A1 (es)	2014-03-28
HRP20251174T1 (hr)	2025-11-21
IL282625A (en)	2021-06-30
US20210177966A1 (en)	2021-06-17
CA3116725A1 (en)	2012-05-10
JP2021104995A (ja)	2021-07-26
PH12013500890A1 (en)	2013-07-01
FI3757126T3 (fi)	2025-10-12
DK3757126T3 (da)	2025-09-29
TW201306864A (zh)	2013-02-16
ES2804624T1 (es)	2021-02-08

Publication	Publication Date	Title
HUE044038T2 (hu)	2019-09-30	Spondilitisz ankilopoetika kezelési eljárásai anti-IL-17 alkalmazásával
PT2768857T (pt)	2020-01-27	Métodos para purificar anticorpos
IL221288A0 (en)	2012-10-31	Therapeutic methods using anti-cd200 antibodies
IL228738A0 (en)	2013-12-31	Antibodies for cancer treatment
PL3424953T3 (pl)	2021-01-25	Lecznicze przeciwciała
ZA201208290B (en)	2013-07-31	Anti-erbb3 antibodies
SMT201800462T1 (it)	2018-11-09	Anticorpi umanizzati anti-cd28
ZA201403108B (en)	2015-11-25	Purification of anti-c-met antibodies
EP2566514A4 (en)	2013-11-27	METHODS OF INHIBITING FIBROSIS WITH ANTI-PAI-1 ANTIBODIES
IL249501A0 (en)	2017-02-28	A process for creating antibodies
PL2632946T3 (pl)	2018-06-29	Sposób wytwarzania pojedynczych domen zmiennych immunoglobulin
LT2696959T (lt)	2017-12-27	Aplinkai nekenksmingas cemento gamybos būdas
SG11201400405TA (en)	2014-04-28	Caninised antibodies and method for the production of same
ZA201208136B (en)	2014-03-26	Humanized il-25 antibodies
EP2714713A4 (en)	2014-10-29	PURIFICATION OF ANTIBODIES
GB201020045D0 (en)	2011-01-12	Method for the treatment of biogas
IL226040A0 (en)	2013-06-27	Methods for generating antibodies to metalloenzymes
ZA201308992B (en)	2021-05-26	Therapeutic antibodies